of less than 6·5 mg per kg) is currently the drug of first choice. If these measures fail, a wide variety of other medications have been advocated. These include thalidomide, dapsone, oral gold, alpha interferon, and retinoids. All have been shown, in at least one study, to produce a good clinical response in patients with DLE who have failed to respond to the combination of topical steroids, sunblocks and hydroxychloroquine. However, in our experience, we have encountered a number of patients with active DLE who have failed to respond to the above treatments. In addition, the toxicity of some treatments, such as thalidomide, oral gold or retinoids, may limit their use. We were therefore interested to assess the potential use of MTX in the management of DLE, which has not been reported previously, and which might be a useful addition to the therapeutic armamentarium for this condition.

Low-dose weekly oral MTX is a relatively safe drug and hepatotoxicity is usually limited to psoriatics whose condition is complicated by a secondary factor such as alcohol excess, diabetes mellitus, arsenic ingestion, or obesity. The American Rheumatism Association does not recommend routine pretreatment liver biopsy for patients with uncomplicated rheumatoid arthritis receiving MTX, as very few problems have been reported with its use in this condition. Side-effects reported in patients with SLE have included neutropenia and oral ulceration, and have tended to be confined to those patients with active disease with renal impairment. Thus, short-term treatment of DLE with MTX is most unlikely to be complicated by any significant side-effects, in the absence of an additional factor. Possible mechanisms of action of MTX in DLE might include inhibition of T-cell activation and the inhibition of migration of inflammatory cells into the affected area.

As only a small number of patients were included in this study, the conclusions drawn must be limited. However, the reasonable response seen in two of the four patients suggests that MTX may be of help in patients with therapy-resistant DLE which has failed to respond to hydroxychloroquine, and in whom other treatments, such as thalidomide, oral gold or retinoids, have either failed or are contraindicated.

Department of Dermatology, Great George Street, Leeds LS1 3EX, U.K.

W.W. Brottmann
M.J.D. Goodfield

References


Transglutaminase-positive cells in psoriatic epidermis during treatment with calcitriol (1α,25 dihydroxy vitamin D₃) and tacalcitol (1α,24 dihydroxy vitamin D₃)

Sin, The keratinization process in human epidermis involves the formation of an insoluble cross-linked protein envelope. Involution, filaggrin and other major precursor proteins of the cornified cell envelope are expressed late during epidermal differentiation. Involution expression starts in the upper spinous cell layers in normal human skin. Filaggrin expression is restricted to the granular layer and the stratum corneum. These and other precursor proteins become cross-linked by the activity of transglutaminase K, the rate limiting enzyme in the formation of the cornified envelope. via ε-(γ-glutamyl) lysine isopeptide bonds.

It has been demonstrated that membrane-associated transglutaminase activity and the number of cross-linked envelopes are markedly increased in psoriatic skin. It is also well established that in psoriatic epidermis involucrin expression is significantly increased, whereas filaggrin expression is decreased or even absent.

In keratinocytes in vitro, it has been demonstrated that cornified envelope formation and transglutaminase activity are enhanced by calcitriol (1α,25 dihydroxy vitamin D₃), tacalcitol (1α,24 dihydroxy vitamin D₃), and calcipotriol (1α,24 dihydroxy vitamin D₃). Recently, we reported that 1α,25 (OH)₂D₃ and 1α,24 (OH)₂D₃ reduce the expression of involucrin and increase filaggrin expression in psoriatic skin.

A mouse monoclonal antibody (1g62) against human keratinocyte transglutaminase (BTL) has become available for the immunoperoxidase staining technique. The aim of the present investigation was to examine the effect of 1α,25 (OH)₂D₃ and of 1α,24 (OH)₂D₃ on the expression of human keratinocyte transglutaminase in vivo during treatment of psoriatic plaques with these derivatives.

Twenty patients with stable psoriasis vulgaris were included in this study. Ten patients were treated with calcitriol in petrolatum (3 µg/g) twice daily. Before treatment, and after 1, 2 and 4 weeks of treatment, punch biopsies (3 mm) were taken from the psoriatic lesions. Calcitriol was obtained from Solvay Duphar, Amsterdam, the Netherlands. The other 10 patients were treated with tacalcitol ointment (4 µg/g) once daily on one half of the body, and the ointment base alone on the other half, for 8 weeks. Before treatment, and after 8 weeks of treatment, punch biopsies (3 mm) were taken from both body halves.

To visualize transglutaminase type I, which is expressed during differentiation of the epidermis, we used immuno-
glutaminase expression was assessed by calculating the ratio positive cell layers/total cell layers of the living epidermis. This procedure was performed at two sites: at the tip of a dermal papilla, and in the interpapillary region. On every slide, two representative areas were examined, and the mean of these observations was assessed. The Wilcoxon ranking test for matched pairs was used for statistical analysis.

The calcitriol-treated lesions showed a statistically significant reduction of transglutaminase expression at the tip of a dermal papilla after 4 weeks of treatment ($P < 0.03$). In the interpapillary region, the transglutaminase staining showed a tendency to decrease after 4 weeks of treatment with calcitriol ($P < 0.075$).

The tacalcitol-treated lesions also showed a statistically significant decrease of transglutaminase expression at the tip of a dermal papilla ($P < 0.03$), whereas the expression in the interpapillary zone was not significantly affected by this treatment ($P < 0.125$). The transglutaminase expression in the biopsies of the lesions treated with placebo did not change significantly ($P = 0.2$ in both areas). Figures 1 and 2 demonstrate the mean values ± the standard error of the mean. Figure 3 shows the distribution of transglutaminase before and after 4 weeks of treatment with calcitriol.

It has been demonstrated that membrane-associated transglutaminase activity and the number of cross-linked envelopes are markedly increased in psoriatic skin—fivefold and tenfold, respectively. Recently, we demonstrated by immunohistochemistry that the number of transglutaminase-positive cells is markedly increased in lesional skin compared with the clinically uninvolved skin of psoriatic patients. The distribution pattern of transglutaminase comprised relatively more cell layers compared with the distribution pattern of involucrin. To date, the trigger for the premature expression of transglutaminase in psoriatic skin has still to be identified. It is remotely possible that involucrin expression stimulates the expression of its cross-linking enzyme directly. Alternatively,
of transglutaminase-positive cells is accompanied by a decrease in the number of calcium and increased production of calcium-positive cells. A redistribution of the number of calcium and increased production of calcium-positive cells can be seen in the increased production of calcium-positive cells. However, the increased production of calcium-positive cells is not accompanied by a decrease in the number of calcium and increased production of calcium-positive cells. This suggests that the increase in calcium production of calcium-positive cells is due to a redistribution of calcium in normal skin.

In the active vitamin D3 analog, transglutaminase activity is enhanced by active vitamin D3 treatment with active vitamin D3 treatment

However, the increased production of calcium-positive cells is not accompanied by a decrease in the number of calcium and increased production of calcium-positive cells. This suggests that the increase in calcium production of calcium-positive cells is due to a redistribution of calcium in normal skin.

In the active vitamin D3 analog, transglutaminase activity is enhanced by active vitamin D3 treatment with active vitamin D3 treatment.
Treatement of recurrent apthous stomatitis with pentoxifylline

Six, Recurrent apthous stomatitis (RAS) is one of the most common diseases affecting the oral mucosa. Many drugs, including analgesics, antibiotics, topical and systemic corticosteroids, dapsone, colchicine and thalidomide, have been used to relieve pain and to reduce the frequency of relapse. They are not always effective, and side-effects are a complicating factor.1 Pentoxifylline (PTX) is a methylxanthine derivative with haemorrhheological and antiinflammatory properties.2 Recent experimental and clinical observations have demonstrated that PTX also has immunomodulating and antiinflammatory activities, which seem to be related, at least in part, to the inhibitory effect of PTX on tumour necrosis factor (TNF)-alpha production.3 Thalidomide, which is one of the treatments of choice for severe RAS,4 also inhibits TNF-alpha production.5 This observation led us to speculate that PTX and thalidomide could share certain therapeutic effects, such as the prevention of RAS.6 Recently, we reported six patients with RAS who were successfully treated with PTX. Oral therapy with PTX (400 mg two—three times daily) suppressed the recurrence of aphthae in five patients, and led to a reduction in the number and duration of ulcers, with symptomatic improvement, in one patient.7 We now report 22 additional cases.

Twenty-two patients (14 women and eight men) between 19 and 75 years of age (mean 34 years), were enrolled in this open study. All the patients were diagnosed as having minor RAS, and had a disease duration of 2—8 years (mean 3.5 years). They all had multiple oral apthous ulcers which lasted for 7—15 days, and experienced recurrences at least every 2 months. Seventeen patients had neither clinical nor analytical evidence of any underlying systemic or cutaneous disease. The remaining five patients suffered from ulcerative colitis (which was treated with low-dose oral corticosteroids and mesalazine), rheumatoid arthritis (treated with nonsteroidal anti-inflammatory drugs), subacute cutaneous lupus erythematosus (treated with topical corticosteroids and sun-screening cream), anorexia nervosa and Parkinson’s disease.

All the patients received oral therapy with PTX at a dose of 400 mg three times daily. Patients were studied monthly for a 6-month period. Two patients (9%) had gastrointestinal intolerance, and the drug was discontinued in the first month. The drug was well tolerated by the remaining 20 patients, including the patient with ulcerative colitis. No relapses of apthous ulcers during the course of treatment were observed in 11 patients (50%), including those cases with anorexia nervosa, ulcerative colitis and subacute cutaneous lupus erythematosus. Six patients (27%) showed recurrence of the lesions during the period of the study, but there was a reduction in the number and duration of ulcers, as well as in the pain and difficulty with eating. Recurrence of apthous ulcers without symptomatic improvement was observed in three cases (14%).

The present study, and our previous observations,8 suggest that continuous PTX treatment can prevent minor RAS, or significantly reduce its severity, in most patients. In addition,